Male Reproductive Cancers
Focal therapy targets may potentially reduce adverse events and provide better cancer control, but previous studies have been limited in scope.
According to experts, PARP inhibition, radiopharmaceuticals, and immunotherapy could revolutionize how prostate cancer is treated in the coming decade.
Treatment with enzalutamide decreased the risk of metastasis or death by 71% in patients diagnosed with nonmetastatic castration-resistant prostate cancer.
A phase 3 trial involving men treated with radiotherapy for intermediate- or high-risk prostate cancer revealed no significant difference in biochemical disease-free survival.
Salvage therapy guided by 68Ga-PSMA11 PET/CT resulted in high biochemical response rates.
Abiraterone plus prednisone was associated with significantly greater PSA progression-free survival among patients who are black compared with white patients.
In a phase 3 trial, Prostvac-V/F did not significantly prolong overall survival among men with asymptomatic or minimally symptomatic mCRPC.
Abiraterone plus leuprolide compared with leuprolide decreased the risk of biochemical recurrence by 38%.
Enzalutamide decreases the risk of clinically meaningful deterioration in HRQoL compared with placebo in men with non-metastatic CRPC, new study finds.
The impact of USPSTF recommendations on the incidence and management of prostate cancer have not yet been fully explored.
Men with Gleason 6 and Gleason 3+4 prostate cancer who undergo radical prostatectomy after a period on active surveillance have similar surgical outcomes.
Following laparoscopic radical prostatectomy, men with posterior index tumors had 76% increased risk of biochemical recurrence vs those with anterior prostate tumors.
A recent article is only the latest in a series of studies drawing attention to the importance of diet in prostate cancer development.
The BMH online survey allows patients to enter comorbidity data at home prior to consultation.
Get the latest treatment regimens for testicular cancer, including options such as carboplatin, EP + cisplatin, BEP, and VIP.
Knowing that food increases the absorption of some therapies presents the possibility of easily — and significantly — lowering treatment costs.
The cause of death was prostate cancer among 18% vs 22% of patients receiving ADT vs ADT plus MP, respectively.
Results from the Prostate Cancer Prevention Trial indicate that the reduced risk for prostate cancer among men assigned to finasteride continued throughout 16 years of follow-up.
Patients in both treatment arms had a PFS of about 9 months.
In this randomized controlled trial, men aged 50 to 69 received an invitation to take a single PSA test or were unscreened.
African Americans have a 60% higher incidence of prostate cancer and are about 2 times more likely to die from the disease.
Seven hundred and fifty-one patients were assigned to the 70.2 Gy group and 748 were assigned to the 79.2 Gy group. The median follow-up was 8.4 years.
A previous study showed that using 5-ARIs to treat benign prostate hyperplasia decreased the risk of low-grade PCa.
Recommendations about population-wide PSA screening are mixed, with some studies suggesting that the potential benefits of early diagnosis are outweighed by overtreatment.
A study could not determine whether one liquid biopsy panel is more accurate than another overall.
Apalutamide is also the first agent to be approved for meeting the primary endpoint of metastasis-free survival.
New diagnostic and therapeutic tools are in development to inform the management of advanced and metastatic disease.
In separate studies, apalutamide, an investigational agent, and enzalutamide prolonged metastasis-free survival in men with non-metastatic castration-resistant prostate cancer.
COMET-1 and COMET-2 previously showed no overall survival benefit with cabozantinib.
It was previously unknown whether chemotherapy or surveillance leads to improved outcomes in prostate cancer post-prostatectomy.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Massage and Cancer
- Pembrolizumab May Lead to Favorable Long-Term Outcomes in Head and Neck Cancer
- Biomarker-Based Blood Test May Extend Reach of CT Screening for Certain Lung Cancers
- Next-Generation Sequencing Adds Value by Detecting More Mutations Than Polymerase Chain Reaction in Melanoma
- Tucatinib May Be A Safe, Novel Treatment for ERBB2/HER2-Positive Breast Cancer